Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2020 Apr 8;55(6):1430–1432. doi: 10.1002/ppul.24767

Clinical characteristics of a case series of children with coronavirus disease 2019

Li Zhu 1, Jian Wang 2, Rui Huang 2, Longgen Liu 3, Haiyan Zhao 4, Chao Wu 2,, Chuanwu Zhu 1,
PMCID: PMC7262135  PMID: 32270592

Abstract

We reported the clinical characteristics of a case series of 10 patients with coronavirus disease 2019 (COVID‐19) aged from 1 year to 18 years. Seven patients had contact with confirmed COVID‐19 family members before onset. Fever (4 [40.0%]) and cough (3 [30.0%]) were the most common symptoms. No patient showed leucopenia and lymphopenia on admission. Pneumonia was observed in chest CT images in 5 (50.0%) patients. Five (50.0%) patients received antiviral treatment. No patient had severe complications or developed a severe illness in our study. Our study indicated that COVID‐19 children present less severe symptoms and have better outcomes.

Keywords: children, coronavirus disease 2019, prognosis

1. INTRODUCTION

In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection spread rapidly among humans worldwide. 1 The epidemiological, radiological, and clinical characteristics of COVID‐10 have been reported in the general population. 2 Elderly patients with comorbidities may be more likely infected by SARS‐CoV‐2 according to previous reports. 3 In addition, the characteristics of COVID‐19 in special populations were also reported. Wei et al 4 reported nine confirmed infants in Wuhan under 1 year of age with a good prognosis. However, to the best of our knowledge, few studies have reported the clinical characteristics of COVID‐19 in children outside of Wuhan. We describe the epidemiological and clinical characteristics of COVID‐19 in a case series of 10 children aged from 1 year to 18 years in Jiangsu province, China.

2. METHODS

Children aged from 1 year to 18 years with confirmed COVID‐19 were retrospectively recruited from 3 designated hospitals in three cities of Jiangsu province, China. All children were confirmed with COVID‐19 between January 24, 2020 and February 22, 2020 based on the criterion of the World Health Organization (WHO) interim guidance. 5

Demographic, epidemiological and clinical data were collected from medical records. All patients were confirmed by quantitative real‐time reverse transcriptase polymerase chain reaction (RT‐PCR) method on throat swab sample or anal swab sample. The protocol of RT‐PCR was consistent with the recommendation of World Health Organization. 5 RT‐PCR was tested in both hospitals and local centers for disease control and prevention.

This study was approved by the ethics committees of these hospitals, with a waiver of informed consent.

3. RESULTS

A total of 10 children with COVID‐19 were included in the study (Table 1). Five (50%) patients were male. The oldest patient is 17 years and the youngest patient is 1 year and 7 months old. Seven patients had contact with confirmed COVID‐19 family members, none of whom visited or lived in Wuhan. The other three children had been living in Wuhan and arrived in Jiangsu within 2 weeks before the diagnosis. No family member had a history of exposure to the Huanan seafood market.

Table 1.

Epidemiologic and clinical characteristics of 10 children with coronavirus disease 2019

Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Patient 9 Patient 10
Age, y 1 y 7 mo 9 11 6 10 4 7 14 12 17
Sex Male Female Female Male Male Male Female Male Female Female
Exposure history
Contact with confirmed family members Yes Yes Yes Yes Yes Yes No Yes No No
Lived in Wuhan No No No No No No Yes No Yes Yes
Onset symptoms and signs
Fever No No No No Yes No Yes Yes No Yes
Cough No Yes Yes No Yes No No No No No
Sore throat No No No No No No No No No No
Headache No No No No No No No Yes No Yes
Shortness of breath No No No No No No No No No No
Vomiting No No No No No No No No No No
Diarrhea No No No No No No No No No No
Laboratory tests
WBC, ×109/L 12.94 8.04 9.1 7.57 6.96 8.14 4.65 5.96 3.85 7.45
Decreased No No No No No No No No No No
Lymphocyte, ×109/L 11.46 2.18 3.22 4.08 3.64 3.68 2.72 1.88 1.71 2.59
Decreased No No No No No No No No No No
ALT, U/L 24 69 41 31 24 31 10.4 12.3 26 13
Increased No Yes Yes No No No No No No No
CRP, mg/L <0.5 <0.5 <0.5 <0.5 <0.5 <0.5 1.47 1.22 0.65 0.67
Increased No No No No No No No No No No
PCT, ng/mL 0.034 0.028 0.026 0.023 <0.02 0.099 0.025 0.024 NA NA
Increased No No No No No No No No NA NA
Chest CT findings
Unilateral pneumonia Yes No Yes No No No No No Yes No
Bilateral pneumonia No No No No No No No Yes No Yes
Treatment
Oxygen therapy No Yes No No No No No No No No
Antiviral therapy No Yes No No No No Yes Yes Yes Yes
Antibiotic therapy No No Yes No No No No No No No
Corticosteroid No No No No No No No No No No
γ‐Globulin No No No No No No No No No No
Outcomes
Hospital discharge Yes No Yes Yes No No Yes Yes Yes Yes
Severe complication No No No No No No No No No No
ICU admission No No No No No No No No No No

Abbreviations: ALT, alanine aminotransferase; CRP, C‐reactive protein; ICU, intensive care unit; NA, not available; PCT, procalcitonin; WBC, white blood cells.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

The most common initial symptoms at the onset of illness were fever (4 [40.0%]), followed by cough (3 [30.0%]) and headache (2 [20.0%]). Other symptoms, including fatigue, sore throat, muscle ache, shortness of breath, or diarrhea were not presented in these patients. Three of 10 (30%) patients had no clinical symptoms before admission, who received COVID‐19 screening due to the contact with confirmed COVID‐19 family members.

No patient showed leucopenia and lymphopenia on admission. Three of 10 patients (30%) had mildly increased levels of alanine aminotransferase (ALT). The peak level of ALT was 69 U/L. Inflammatory markers including C‐reactive protein and procalcitonin were normal in all patients. All patients received a chest CT examination on admission. Typical findings of chest CT images were observed in five (50.0%) patients. Of the five patients, two (40.0%) had bilateral and one (20.0%) had unilateral ground‐glass opacity.

Oxygen therapy was required in one (10.0%) patients. Five (50.0%) patients received antiviral treatment, including lopinavir/ritonavir (n = 4; 40.0%), interferon α‐2b (n = 4; 40.0%), and oseltamivir (n = 1; 10.0%). One (10.0%) patient was given antibiotic treatment and no patient was treated with corticosteroid or gamma globulin. As of February 25, 2020, 5 (50.0%) of 10 patients have been discharged, and 5 (50.0%) patients remained hospitalized. No patient had severe complications and no patient developed a severe illness in our study. No patient was admitted to the ICU or deceased in our study.

4. DISCUSSION

The current study reported the clinical characters of 10 children with confirmed COVID‐19 from Jiangsu province, China. Most of the patients had contact with confirmed COVID‐19 family members in our study, suggesting that family clustering infection is common in infected children and the protection for children who had a confirmed family member is important.

Consistent with adult patients, fever and cough were the most common symptoms at the onset of illness. 2 However, asymptomatic infection is common in children patients. The illness in all children was mild and no severe complication occurred. Previous studies in adult patients reported intensive care unit (ICU) admission ranged from 26.1% to 32% and the fatality rate ranged from 4.3% to 15%. 3 Our results suggested that the outcomes of children were better than adult patients. Similarly, Wei et al 4 reported nine infants and no patient was admitted to the ICU or had any severe complications. The children rarely combine comorbidities and may be less susceptible to developing severe illness than elderly patients. 4

Although the antiviral effect was uncertain, 50.0% of patients received antiviral therapy in this study. However, the benefit of antiviral therapy for COVID‐19 remains unclear. In addition, 10.0% of patients received empirical antibacterial therapy, and no patient received corticosteroids or gamma globulin due to the mild illness.

There were several limitations to this study. First, the sample size is small and only 10 childhood patients were enrolled. The results need to be confirmed by a larger sample study. In addition, as of February 25, 2020, five patients remained in hospital and the clinical outcomes were not available at the time of analysis. Thus, the risk factors of poor prognosis for children patients remains unknown.

5. SUMMARY

In conclusion, compared with adult patients, COVID‐19 children present less severe symptoms and have better outcomes. Our results provide valuable information to understanding the epidemiological and clinical features of COVID‐19 in children.

CONFLICT OF INTERESTS

The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS

Concept and design: CZ, CW. Acquisition, analysis, or interpretation of data: LZ, JW, RH, LL, HZ. Drafting of the manuscript: LZ, JW, RH. Critical revision of the manuscript for important intellectual content: CZ, CW. Statistical analysis: JW. Administrative, technical, or material support: LL, HZ. Supervision: CZ, CW.

ACKNOWLEDGMENT

This study was supported by the Fundamental Research Funds for the Central Universities (No. 14380459).

Zhu L, Wang J, Huang R, et al. Clinical characteristics of a case series of children with coronavirus disease 2019. Pediatric Pulmonology. 2020;55:1430–1432. 10.1002/ppul.24767

Li Zhu, Jian Wang, and Rui Huang contributed equally to this study.

Contributor Information

Chao Wu, Email: dr.wu@nju.edu.cn.

Chuanwu Zhu, Email: zhuchw@126.com.

REFERENCES


Articles from Pediatric Pulmonology are provided here courtesy of Wiley

RESOURCES